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Introduction: Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma in
situ (DCIS) of the breast and is associated with poorly differentiated tumors and adverse prognosis features. This
study aimed to determine the molecular effects of the HER2 inhibitor lapatinib in patients with HER2 positive DCIS.
Methods: Patients with HER2 positive DCIS received 1,500 mg daily of lapatinib for four consecutive weeks prior
to surgical resection. Magnetic resonance imaging (MRI) was used to determine changes in tumor volume. The
molecular effects of lapatinib on HER2 signaling (PI3K/AKT and RAS/MAPK pathways), cell proliferation (Ki67 and
p27) and apoptosis (TUNEL) were determined in pre and post-lapatinib treatment samples.
Results: A total of 20 patients were included. Lapatinib was well tolerated with only minor and transient side
effects. The agent effectively modulated HER2 signaling decreasing significantly pHER2 and pERK1 expression,
together with a decrease in tumor size evaluated by MRI. There was no evidence of changes in Ki67.
Conclusions: Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of
HER2 and RAS/MAPK signaling pathway.
Trial registration: 2008-004492-21 (Registered June 25th 2008).Introduction
Data from the National Cancer Database estimate that
12 to 15% of newly diagnosed breast cancer in the US
today is ductal carcinoma in situ (DCIS) [1]. DCIS is
defined as a malignant proliferation of ductal cells of the
breast that does not invade through the basal membrane.
DCIS rarely presents as a palpable mass in the breast but
is associated with microcalcifications seen in mammog-
raphy. The broad implementation of screening programs
has resulted in an increase from 5 to 25% in the number
of patients diagnosed with this disease [2,3].
Conventional management of DCIS includes surgical
resection by either mastectomy or breast-conserving sur-
gery and radiation therapy, depending on the extent of
the disease [4,5]. Bilateral breast magnetic resonance
imaging (MRI) is being used preoperatively with increas-
ing frequency in women with DCIS, where it has shown
high sensitivity for detecting high-grade lesions [6].* Correspondence: lestevez@hmhospitales.com
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unless otherwise stated.Patients with hormone receptor-positive tumors benefit
from adjuvant treatment with tamoxifen that decreases
local and contralateral tumor failure [2-5]. Despite its
excellent prognosis, in up to 10% of patients, DCIS will
recur, often with invasive carcinoma [7].
One of the salient features of DCIS is the high expression
of human epidermal growth factor receptor 2 (HER2).
Although globally 20 to 30% of patients with invasive
breast cancer express HER2, the expression is as high
as 60 to 70% in patients with high-grade/comedo-type
DCIS [8]. Expression of HER2 is associated with high
proliferative grade, comedo-necrosis, and p53 mutation,
and is inversely associated with the expression of hormone
receptors [9,10].
HER2 belongs to a receptor family that includes HER1,
HER2, HER3, and HER4, respectively. These molecules
are transmembrane tyrosine kinase receptors with partial
homology that regulate cell growth and survival, as well
as adhesion, migration, differentiation, and other cellular
responses. HER2 are the preferred dimerization partners
for the other HER family members [11]. When HER2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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vated) tyrosine residues on the intracellular domain of
HER2 activate the lipid kinase phosphoinositide 3-kinase
(PI3K), which results in activation of the enzyme AKT
transforming factor (AKT) promoting cell survival [11].
In contrast, when HER1 is the chosen partner for
dimerization, the complex HER1-HER2 preferentially
activate the rat sarcoma (RAS)/rapid accelerated fibro-
sarcoma (RAF)/mitogen-activated protein kinase (MAPK)
cascades promoting cell proliferation [12]. HER2 is a
validated therapeutic target in invasive breast cancer,
leading to the hypothesis that inhibition of HER2 through
anti-HER2 therapy could be beneficial for patients with
DCIS.
Lapatinib, a reversible dual-kinase inhibitor of epidermal
growth factor receptor (EGFR) and HER2, has activity
in HER2-overexpressing breast cancer and is approved
in combination with capecitabine for the treatment of
patients with metastatic disease [13]. In early pharma-
codynamic clinical studies, administration of lapatinib to
patients with advanced breast cancer resulted in inhibition
of HER2 signaling and induction of apoptosis [14-18]. At
the recommended dose, the drug is well-tolerated with
skin rash and diarrhea as the predominant toxicities. In
rare cases, there were liver and cardiac adverse events [19].
The central hypothesis of the present study is that
lapatinib inhibits HER2 signaling in DCIS patients result-
ing in cell proliferation arrest and apoptosis. The primary
objective of the trial was to determine the pharmacody-
namic effects of a 4-week course of lapatinib administered
preoperatively to patients with HER2-positive DCIS
measuring protein expression of phospho extracellular-
regulated kinase (pERK), phosphor-AKT (pAkt) and prolif-
erative/apoptosis markers at baseline and post treatment.
Secondary analysis included assessment of tumor response
by MRI and the correlation with molecular biomarkers.
Methods
Study design
This study was a prospective, open-label, phase II trial,
conducted at the Centro Integral Oncológico Clara Campal,
Hospital Universitario Madrid, between December 2009
and June 2010. Patients were required to give written
informed consent before inclusion in the study. The trial
was conducted following the guidelines of the local Ethical
Review Board and the Spanish Ministry of Health, and in
accordance with Good Clinical Practices and the tenets of
the Declaration of Helsinki. The protocol was approved
by the Clinical Research Ethic Committee of Hospital
Universitario Madrid Norte Sanchinarro (Madrid, Spain).
Eligibility criteria
Female patients with pathological diagnoses of HER2-
positive DCIS, according to American Society of ClinicalOncology/College of American Pathologists (ASCO/CAP)
guidelines [20], scheduled to undergo surgery by either
lumpectomy or mastectomy were eligible. Other eligi-
bility criteria included age ≥18 years, Eastern Cooperative
Oncology Group (ECOG) performance status 0 to 2;
normal hematological (absolute neutrophil count ≥1.5
cells × 109/L, platelets ≥75 cells × 109/L, and hemo-
globin ≥9 g/dl), liver (bilirrubin ≤1.25 × upper limit of
normal (ULN), aspartate transaminase (AST) and alanine
transaminase (ALT) ≤2.5 × ULN and alkaline phosphat-
ase ≤2.5 × ULN) and renal (creatinine ≤2.0 mg/dL or
creatinine clearance >40 ml/min); and normal left
ventricular ejection fraction. Lactating and pregnant
women were excluded. Other exclusion criteria included
previous treatment with lapatinib, contralateral breast
mass, presence or suspicion of invasive carcinoma, axillary
lymph nodes, malabsorption syndrome that could inter-
fere with lapatinib exposure, any other serious cardiac,
neurological or psychiatric disorder that in the investiga-
tor's opinion could compromise treatment safety and
compliance, and concomitant use of CYP3A4 interacting
agents. Women of fertile age were required to use appro-
priate contraception methods.
Treatment administration
Patients received lapatinib as single agent administered
orally for 28 days (4 weeks) at a dose of 1,500 mg per day
divided into six 250-mg capsules, following the package
insert recommendations. Missed doses were not made up
and no dose reductions were allowed. Treatment compli-
ance was recorded in a patient diary. Patients who for
whatever reason, received less than 80% of the prescribed
dose were replaced.
Study procedures and follow up
Patients with histologically confirmed HER2-positive
DCIS with measurable residual microcalcifications (1 cm)
on mammography after initial diagnostic biopsy were
counseled about the study. The first MRI of the breast
was also performed after the diagnostic biopsy procedure.
Written informed consent was obtained from all patients
before study inclusion. Screening studies, including safety
laboratory measurements and assessment of left ven-
tricular ejection fraction (LVEF) were performed. Patients
were visited on a weekly basis while on medication to
monitor treatment compliance and toxicity. Physical
examination, hematology and blood chemistry analysis
were performed weekly. Treatment-related toxicities were
recorded according to the National Cancer Institute (NCI)
Common Toxicity Criteria (CTC) version 3 criteria and
managed as per-package insert. The second breast MRI
was performed on day 28 following the end of lapatinib
treatment. Patients were schedule for surgery 3 to 4 weeks
(range 1 to 4) after treatment completion.
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Imaging studies (mammography and breast MRI) were
both performed prior to biopsy procedure and definitive
surgery, to permit an unbiased interpretation. Mammog-
raphy and MRI scans were read and scored independently
by one expert breast radiologist. All MRI examinations
were performed on a commercially available 3-T system
(MR Systems Achieva, Version 2.6.3.6; Philips Electronics
2010). Images were evaluated for areas of abnormal
enhancement in the breast using previously described
interpretation criteria [21]. Response assessment was
defined according to response evaluation criteria in solid
tumors (RECIST) [22].
Tissue processing and biological studies
Biological markers were measured before and after lapa-
tinib treatment in order to evaluate treatment-induced
changes. A fresh core needle-biopsy was obtained from
each patient prior to lapatinib treatment. Tissue samples
were immediately fixed in formalin after the extraction
in the radiological room and embedded in paraffin
(formalin-fixed paraffin-embedded, FFPE) for molecular
tests. After lapatinib treatment, molecular tests were
analyzed in representative tumor areas of the surgical
specimen. In order to avoid suboptimal fixation of surgical
specimens and resulting problem of loss of immunoreac-
tivity of phosphoproteins in paraffin samples, surgical
samples were processed as follows: tissue samples were
moved from the operating room to the pathology room as
soon as surgeons removed the sample from the patient.
The samples were sliced at intervals of 5 mm and placed
in large volume of formalin for 18 to 24 hours to allow the
maximum penetration of formalin and to obtain the
optimum fixation of samples. Median time from collection
of samples was 8 minutes (range 1 (cores) to 15 (surgical
specimens) minutes).
Fluorescence in situ hybridization (FISH)
To assess HER2 and EGFR amplification, fluorescence in
situ hybridization (FISH) was performed in all samples
using the PathVysion HER2 DNA Probe kit (Vysis) and
the EGFR Probe kit (Vysis) with the DAKO Histology
FISH Accessory Kit. HER2 gene amplification was con-
sidered when the ratio HER2/CEP 17 was ≥2.2. EGFR
gene amplification was considered when the ratio EGFR/
CEP 7 was ≥2.
Immunohistochemistry (IHQ)
Immunohistochemical studies were assessed in FFPE
tissue for the following primary antibodies: HER2 (SP3
clone; 1:100 dilution; Spring); pHER2 (6B12 clone; 1/100
dilution; Cell Signaling Technology); EGFR (SPM341 clon;
1:25 dilution; Spring), phosphor-EGFR (pEGFR) (Tyr992)
(Polyclonal; 1:25 dilution; Cell Signaling Technology),AKT (11E7 clone; 1:50 dilution; Cell Signaling Technology);
pAKT (Ser473)(736E11 clone; 1:50 dilution; Cell Sig-
naling Technology), p44/42 MAPK (ERK 1) (137 F5
clone; 1:200 dilution; Cell Signaling Technology), pp44/42
MAPK (pERK1) (Thr202/Tyr204; E10) (20G11 clone;
1:200 dilution; Cell Signaling Technology), phosphatase
and tensin homolog (PTEN) (28H6 clone; 1/100 dilution;
Novocastra), p27 (SX53G8 clone; Ventana-Ready to use),
and Ki67 (30 to 9 clone; Ventana-Ready to use). All anti-
bodies except p27, Ki67 and HER2 were scored based
on intensity from 0 to 3+ and percentage of positive
cells to generate a score (H-score) that ranges from 0
to 300 by multiplying these two parameters. p27 and
Ki67 proliferative index were reported as percentage of
positive nuclei in hot-spot areas. HER2 was scored
following ASCO/CAP scoring criteria for immunohisto-
chemistry. For biomarkers determined by H-score, overex-
pression was considered for scores ≥150. The percentage
of stained nuclei was evaluated independently of the
intensity for Ki67 and p27 (cutoff ≥15%).
Mutational analysis
Real-time polymerase chain reaction (PCR) mutational
screening for phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA) (exons 9 and
20) was carried out using PCR and direct sequencing
following standard protocols [23].
Apoptosis cell analysis
Terminal deoxynucleotidyl transferase-mediated deoxyur-
idine triphosphate-biotin nick-end labeling (TUNEL) was
performed according to the manufacture instructions
(Roche Diagnostics, Indianapolis, IN) [24]. The number of
apoptotic cells was determined in each sample.
Statistical and data analysis
This was a single-arm phase-II study to test the hypothesis
that lapatinib inhibits the HER2 pathway and induces
apoptosis in patients with HER2-positive DCIS. The
primary endpoint of the study was the pharmacodynamic
effect of the drug on cell signaling, proliferation and apop-
tosis. The secondary endpoints included tumor changes
on MRI. A sample size of 20 patients was arbitrarily
selected for this study. For the analysis of the primary
endpoint, each biomarker was evaluated before and
after treatment and was summarized using descriptive
statistics. A decrease or increase in the expression of
each single biomarker was determined as a change in
the H-score. The differences in this parameter before and
after treatment were compared with the paired student
t-test. The SPSS v.19 statistical program was used for
all statistical analyses. A two-tailed value of P <0.05 was
considered statistically significant.
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Patient characteristics
A total of 20 patients, whose principal characteristics
are listed in Table 1, were enrolled. Most patients had
high-grade DCIS of non-comedo-type carcinoma and
approximately half (60%) of the subjects had positive
hormone receptors.
Treatment compliance, safety and type of surgery
performed
Seventeen patients completed the prescribed treatment.
One patient received 250 mg daily dose instead of the
1,500 mg dose. In addition, two patients interrupted
treatment by mistake (miss treatment on day 3 and on
day 10) and unrelated side effect. Overall, the treatment
was well-tolerated with no episode of grade-3 toxicity.
The most frequent adverse events were skin reaction,
with 35% of patients experiencing grade-1 rash, and
gastrointestinal toxicity, with 50% of patients experien-
cing grade-1 to grade-2 diarrhea. The types of surgery
performed were: conservative surgery (n = 13, 65%) and
mastectomy (n = 7, 35%).
Biomarkers before lapatinib treatment
All the patients were positive for HER2 gene amplification
with a median ratio of 7 (range 4 to 11.8). None of the
patients had positive EGFR FISH, therefore, it was not
evaluated on definitive surgery. At baseline, 16 patients
(94%) had pHER2 overexpression, 8 patients (42%) had
pAKT overexpression and 7 patients (37%) had pERK1Table 1 Patients’ baseline characteristics
Characteristic Value
Age, median (range) 51 (38 to 68)
Eastern Cooperative Oncology Group
performance status, number of patients
0 20
Histological subtype, number of patients
Comedo carcinoma 7
Non-comedo carcinoma 13










Unknown 1cytoplasmatic overexpression. PTEN was not expressed
in four patients (21%). Sixteen patients (84%) had
Ki67 ≥ 15%, whereas low p27-staining (<15%) was observed
in half of tumors. PI3KCA mutations were detected in only
one patient (6%).
Effects on signaling pathways, cell proliferation, and
apoptosis
After 4 weeks of lapatinib treatment surgery was performed
in the 20 patients. No evidence of carcinoma in situ was
noted in two patients after definitive surgery. Biomarkers
were evaluated in the 18 remaining patients. Tables 2 and 3
summarize the effects on signaling pathways in each patient
individually and in the overall population, respectively.
With regard to the HER2 signaling pathway, 13 patients
had pre- and post-treatment samples for pHER2 assess-
ment. Overall, there was a statistically significant decrement
in pHER2 mean H-score from 237.08 pre-treatment to
79.85 post-treatment (P <0.001). Of these 13 patients,
12 had pHER2 overexpression as defined in the study
(H-score ≥150) and in 9 of them there was a reduction
of <150 after treatment (Figure 1). Regarding the
pERK1, 16 patients had paired samples before and after
treatment. In the overall population with matched spec-
imens there was a statistically significant decrease in
the mean H-score from 117.44 pre-treatment to 45.19
post-treatment (P <0.008). pERK1 expression decreased
from a H-score ≥150 to an H-score <150 in five our seven
patients (Figure 2). Individually, three patients showed
increased expression and in two patients no changes were
detected in global matched specimens. Regarding pAKT,
in 15 paired samples before and after treatment, no signifi-
cant differences in the H-score (P <0.620) were detected.
In these matched samples, in four patients with pAKT
overexpression at baseline, two had a decrease in the
H-score below 150 after treatment. Finally, with regard
to biomarker correlation, four out of nine patients (44%)
with pHER2 reduction (H-score ≥150 to H-score <150),
also presented a decrease in pERK1 expression with almost
no changes in pAKT expression. Interestingly, one patient
with marked inhibition of pHER2 and pERK1 paradoxically
had a increase in pAKT.
Apoptosis index through a TUNEL assay was only per-
formed in eight patients due to insufficient specimens and
to three of them having an increase in apoptotic levels. The
Ki67 index was analyzed before and after treatment in 16
patients with no significant differences in the global popula-
tion. Likewise, the expression of p27 did not change sig-
nificantly before and after lapatinib treatment (Table 3).
Figure 3 depicts changes in the evaluated tumor biomarkers.
Treatment response assessed by MRI
All the patients included in this study underwent MRI
before and after lapatinib treatment. MRI findings at the
Table 2 Changes in H-score in pHER2, pERK1 and pAKT
Patient number pHER2 expression pERK1 expression
Pre-lapatinib Post-lapatinib Pre-lapatinib Post-lapatinib
Intensity Percentage H-score Intensity Percentage H-score Intensity Percentage H-score Intensity Percentage H-score
1 N/A N/A N/A 2+ 90% 180 3+ 26% 78 1+ 46% 46
2 3+ 91% 273 3+ 90% 270 3+ 77+ 231 2+ 76% 152
3 3+ 90% 270 2+ 43% 86 2+ 80% 160 1+ 2% 2
4 3+ 90% 270 1+ 77% 77 1+ 10% 10 1+ 30% 30
5 3+ 90% 270 N/A N/A N/A 1+ 10% 10 N/A N/A N/A
6 N/A N/A N/A 3+ 90% 270 N/A N/A N/A 2+ 10% 20
7 2+ 47% 94 1+ 5% 5 1+ 20% 20 1+ 8% 8
8 3+ 90% 270 N/A N/A N/A 0 0 0 0 0 0
9 3+ 90% 270 0 0 0 1+ 80% 80 0 0 0
10 3+ 50% 150 0 0 0 1+ 90% 90 0 0 0
11 3+ 73% 219 N/A N/A N/A 1+ 10% 10 N/A N/A N/A
12 N/A N/A N/A 1+ 5% 5 0 0 0 0 0 0
13 2+ 90% 180 N/A N/A N/A 1+ 10% 10 N/A N/A N/A
14 3+ 90% 270 1+ 10% 10 1+ 80% 80 2+ 90% 180
15 3+ 90% 270 0 0 0 2+ 95% 190 0 0 0
16 3+ 95% 285 3+ 90% 270 2+ 95% 190 0 0 0
17 3+ 50% 150 2+ 50% 100 1+ 95% 190 0 0 0
18 3+ 95% 285 0 0 0 2+ 55% 110 0 0 0
19 3+ 75% 225 1+ 10% 10 3+ 70% 210 2+ 10% 20













Table 2 Changes in H-score in pHER2, pERK1 and pAKT (Continued)
Patient number pAKt expression
Pre-lapatinib Post-lapatinib
Intensity Percentage H-score Intensity Percentage H-score
1 1+ 5% 5 1+ 40% 40
2 1+ 80% 80 2+ 95% 190
3 2+ 50% 100 3+ 3+ 285
4 2+ 95% 190 2+ 95% 190
5 3+ 90% 270 N/A N/A N/A
6 N/A N/A N/A 1+ 95% 95
7 2+ 90% 180 1+ 95% 95
8 2+ 95% 190 N/A N/A N/A
9 1+ 90% 90 1+ 90% 90
10 3+ 90% 270 1+ 95% 95
11 3+ 90% 270 N/A N/A N/A
12 0 0 0 0 0 0
13 3+ 90% 270 N/A N/A N/A
14 0 0 0 1+ 95% 95
15 0 0 0 0 0 0
16 1+ 95% 95 1+ 95% 95
17 1+ 95% 95 1+ 95% 95
18 1+ 95% 95 1+ 90% 90
19 1+ 95% 95 1+ 95% 95
20 3+ 100% 300 3+ 100% 300













Table 3 Biomarker analysis in matched specimens
Biomarker Number Mean SD P-value
Ki67
Pre-lapatinib 16 26.81 12.303 0.051
Post-lapatinib 16 32.44 14.166
p27
Pre-lapatinib 15 17.67 21.672 0.127
Post-lapatinib 15 8.73 15.050
pHER2
Pre-lapatinib 13 237.08 63.357 0.000
Post-lapatinib 13 79.85 104.311
pERK-1
Pre-lapatinib 16 117.44 84.806 0.005
Post-lapatinib 16 45.19 84.673
pAKt
Pre-lapatinib 15 106.33 93.512 0.620
Post-lapatinib 15 117.00 88.657
pHER2, phospho human epidermal growth factor receptor 2; pERK1, phosphor
extracellular-regulated kinase 1.
Figure 1 Phospho human epidermal growth factor receptor 2 (pHER2)
(B) Negative expression after lapatinib treatment.
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Data System (BIRADS)-2 in eight patients with no evidence
of abnormal images. These eight patients presented also
with BIRADS-2 in the second MRI performed after lapati-
nib treatment. The remaining 12 patients had abnormal
MRI before lapatinib treatment. The most common abnor-
mality consisted of a non-nodular density with focal, linear,
ductal, segmental or diffuse aspect. Of these 12 patients, 9
had a decrease in tumor volume after lapatinib treatment
when both MRI studies were compared (Figure 4). In
addition, in five out of nine patients (56%) with a decrease
in pHER2 expression, a reduction in tumor volume on
MRI, or signal intensity, was also observed. The same situ-
ation was found in two patients (50%) with reduced pERK1
where a decrease in the signal and tumor size on MRI was
also observed (Table 4).Discussion
This study is the first to report the use of neoadjuvant
lapatinib for patients with HER2-positive DCIS. This phar-
macodynamic study aimed to determine the molecularprotein expression. (A) Positive expression before lapatinib treatment.
Figure 2 Phosphor extracellular-regulated kinase 1 (pERK) protein expression. (A) Positive expression before lapatinib treatment.
(B) Negative expression after lapatinib treatment.
Figure 3 Changes in biomarkers before and after lapatinib. pHER2, phospho human epidermal growth factor receptor 2; pERK1, phosphor
extracellular-regulated kinase 1.
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Figure 4 Treatment response assessed by MRI before (A) and after (B) lapatinib treatment.
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HER2-positive DCIS. Using a preoperative window of
treatment administration for 4 weeks prior to surgical
resection, the study showed that the agent is effective
in downregulating the HER2 pathway, with slight ten-
dency in the RAS/MAPK pathways with virtually no effect
against the PI3K/AKT pathway. In addition, the agent
induced apoptosis as previously seen in invasive breast
cancer; however the number of patients was too small to
draw any strong conclusions. These molecular effects
were associated with significant tumor regression on MRI.
The antitumor effects of HER2 inhibitors require the
modulation of key signaling pathways and cell cycle/apop-
tosis regulatory molecules that mediate the transforming
effects of HER2 activation. Recent data in invasive breast
cancer support the observation that activation of the PI3K
pathway or loss of phosphatase and tensin homolog
(PTEN) is associated with resistance to trastuzumab
[25,26]. Mechanisms for lapatinib resistance are less
well-established. In a recent trial that aimed to evaluate
the differential effects of trastuzumab and lapatinib
under low and normal PTEN conditions in HER2-
overexpressing breast cancer cell lines, lapatinib was
effective and decreased both pMAPK and pAKT under
low PTEN conditions. In addition, lapatinib showed a
significant decrease in Ki67 [27]. As opposed to these
findings, the results in the present study showed an in-
crease in Ki67 after lapatinib treatment. It is difficult to
explain such results based on well-established scientificevidence reported in the literature as well as on the
mechanism of action of lapatinib. Therefore, it is impera-
tive to confirm such results in other patient cohorts that
receive the same treatment scheme.
A similar trial with trastuzumab in HER2-positive DCIS
was conducted at the MD Anderson Cancer Center in
Houston by Kuerer et al. [28]. In that study, a single
loading dose of 8 mg/kg of trastuzumab was adminis-
tered to test the biological effects of the agent on DCIS
3 to 4 weeks before surgical resection. In that study, 12
patients received the study drug and 12 patients served
as controls with no treatment. Pre- and post-treatment
tissues with DCIS were studied for proliferation and
apoptosis in patients treated with trastuzumab. The
conclusion was that single-dose monotherapy with
trastuzumab for patients with HER2-positive DCIS
does not result in significant clinical, histologic, prolif-
erative, or apoptotic changes, but results in antibody-
dependent cell-mediated cytotoxicity (ADCC)-mediated
response through natural killer (NK) cells, and may also
induce humoral immunity in a T-cell-dependent
manner.
One of the weaknesses of the present study is the lack
of a control group. The fact that the present study was
performed in only one institution, and not being a multi-
center study, prevented the recruitment of a control arm
of DCIS untreated patients.
The prognosis of patients with DCIS with conventional
surgical and medical treatment is very good and results
















NA No NA NA
2 PR No No No No
3 PR Yes Yes Yes Yes
4 PR Yes No Yes No
5 No
change*
NA NA NA NA
6 No
change*
NA NA NA NA
7 No
change*
No No NA NA
8 PR No No No No
9 PR Yes No Yes No
10 PR Yes No Yes No
11 PR NA NA No No
12 No
change*
NA No NA NA
13 No
change*
NA NA NA NA
14 SD Yes No No No
15 No
change*
Yes Yes NA NA
16 SD No No No No
17 PR Yes Yes Yes Yes
18 PR Yes No Yes No
19 No
change*
Yes Yes NA NA
20 SD No No No No
pHER2, phospho human epidermal growth factor receptor 2; pERK1, phosphor
extracellular-regulated kinase 1; SD, stable disease (response evaluation criteria
in solid tumors (RECIST) criteria); NA, not applicable; PR, partial response
(RECIST criteria); no change*, patients with Breast Imaging Reporting and Data
System (BIRADS)-2 at diagnosis.
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extensive disease and aggressive tumors, however, need
a mastectomy for full tumor eradication. Interestingly,
DCIS has HER2 amplification with higher frequency
than invasive tumors and this HER2-positive DCIS is
often associated with comedo DCIS which carries twice
the risk of local recurrence as compared to non-comedo
DCIS [29,30]. Because of the availability of HER2 inhibi-
tors for cancer treatment, testing whether or not these
agents are effective in HER2 DCIS is reasonable. However,
given the excellent prognosis of this disease, determining
their clinical effect will require a large and lengthy study.
In this sense, the ongoing National Surgical Adjuvant
Breast Project (NSABP) B-43 phase-III randomized trial
in patients with HER2-overexpressing DCIS tests theefficacy of adding trastuzumab to conventional surgical
and radiation therapy treatment.
The present study used a preoperative 4-week window
between diagnosis and definitive surgery to assess bio-
marker modulation. Data from the literature have shown
that tumor manipulation due to diagnostic procedures such
as core biopsies do not induce either molecular changes or
changes in biomarker determination in the post-treatment
biopsy [31]. However, loss of immunoreactivity of phos-
phorylated antibodies in paraffin samples may produce
significant differences in the results associated with the
inappropriate elapsing time of sample fixation. In fact,
extreme loss of immunoreactive p-Akt and p-Erk1/2 during
routine fixation of primary breast cancer has been reported
[32]. However, the present study utilized optimum elapsing
time for sample fixation in order to overcome this problem.
In vitro studies have shown that blockade of EGFR
and HER2 receptors by monoclonal antibodies inhibits
cell proliferation. In our study, lapatinib affected HER2
signaling pathways and downregulated the RAS/MAPK
cascade throughout moderate reduction in pERK1 protein
expression, with no effect in pAKT expression. These
biological effects were reflected in signal reduction on
MRI. A paradoxical activation of pAKT was observed
in one patient with inactivation of pHER2 and pERK1.
This negative feedback-loop has been recently described
as resulting from HER3 hyperactivation, suggesting that
dual inhibition of both pathways should be the most
adequate and effective therapy [33].
Several important issues, including the optimal bio-
marker, methods to determine such biomarkers, and
scores to discriminate between positive and negative bio-
markers, remain unknown. Unlike for HER2 testing, for
which there is currently an international consensus for
positive or negative status, there is no consensus on
other biomarkers in the HER2 signaling pathway that are
indicative of pathway inhibition [34]. The present study
evaluates the downregulation of biomarkers in the RAS/
MAPK and PI3K/AKT pathways by IHC before and after
lapatinib administration in order to determine the mech-
anism of action of this drug in DCIS. The result of this
study is that lapatinib results in inhibition of HER and
RAS/MAPK pathways with no effect in PI3K/AKT as
well as the Ki67 proliferative index. However, there may
be other elements in the HER signaling pathway that are
more relevant to the actions of lapatinib. In addition, we
have arbitrarily selected an H-score cutoff point to deter-
mine positive and negative expression, which may not
necessarily be biologically relevant. A study correlating
biomarker modulation with pathological response may
be more informative in that regard. The fact that over
half of the patients with pHER2 downregulation had a
reduction in tumor size measured by MRI might indicate
a possible activity of lapatinib in DCIS. Indeed, two
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this study. While we cannot rule out that these small
tumors may have been resected with the diagnostic
biopsy, it suggests that lapatinib is effective in this
setting. Therefore, other methods to assess biological
activity such as gene expression profile, albeit more
expensive and time-consuming, may be more inform-
ative. Finally, the molecular events leading to significant
tumor regression on MRI were essentially not captured
by this study. This may require a larger study and the use
of more sensitive and comprehensive molecular tests.
The fundamental question now, having documented
drug safety and molecular effects, is what to do next.
Certainly, a randomized clinical trial comparing lapatinib
versus no treatment in HER2-amplified poor-prognosis
DCIS with local failure, as the primary endpoint would
be required before this treatment can be recommended.
Because of the excellent prognosis, the study would
include a large number of patients, with a long follow
up. Because lapatinib is associated with tumor regression
in this setting, a trial assessing whether preoperative
administration of the agent results in tumor down-staging,
increasing the proportion of patients who can have a
breast-sparing procedure, would also be interesting.
To our knowledge, this is the first study evaluating the
role of neoadjuvant lapatinib in DCIS. Despite the short
half-life of lapatinib (24 hours), its molecular effect in
tumoral cells was observed beyond the expected time
(4-week period between the last dose of lapatinib and
the time of surgery). This phenomenon would indicate
that the molecular changes induced by lapatinib are
maintained over time. However, this hypothesis should
be confirmed with further research.
Conclusions
The present study shows the feasibility of a short-window
treatment with a targeted agent in patients with DCIS.
The results demonstrate that standard-dose lapatinib re-
sults in signaling modulation by decreasing the RAS/
MAPK signaling pathway in patients with HER2-positive
DCIS. Additional studies are needed to determine if this
strategy results in improved patient outcome.
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